541304 — Indo US Bio-Tech Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMicro CapNeutral

Annual income statement for Indo US Bio-Tech, fiscal year end - March 31st, INR millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	ARS	ARS	ARS	ARS	PRESS
Standards:	IAS	IAS	IAS	IAS	—
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	398	401	501	617	728
Cost of Revenue
Gross Profit	79.2	148	139	166	235
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Other Operating Expenses
Total Operating Expenses	360	348	438	532	628
Operating Profit	37.5	52.6	63	85.5	99.9
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	28.6	41.3	53.1	73.9	88
Provision for Income Taxes
Net Income After Taxes	25.3	51	50.6	72.4	82.5
Net Income Before Extraordinary Items
Net Income	25.3	51	50.6	72.4	82.5
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	25.3	51	50.6	72.4	82.5
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	1.74	3.51	4.14	3.75	4.12
Dividends per Share